Skip to main content
PMC home page
NPJ Parkinson's Disease logoLink to NPJ Parkinson's Disease
. 2021 Jul 21;7:63. doi: 10.1038/s41531-021-00202-w

Case-control study of hypertension and Parkinson’s disease

Yuen-Fann Ng 1,2, Ebonne Ng 2, Ee-Wei Lim 2, Kumar M Prakash 1,2, Louis C S Tan 1,2, Eng-King Tan 1,2,✉
PMCID: PMC8295270  PMID: 34290246

Abstract

We evaluate the association of hypertension with PD in an Asian population and performed a meta-analysis on similar studies to address the effect of hypertension on PD risk. A matched case-control study involving 1342 Chinese subjects (671 PD and 671 age and gender-matched controls (with a mean age of 63.9 ± 9.7 and 63.5 ± 9.8 years, and identical proportion of gender distribution) was conducted. Hypertension increases PD risk by 1.9 times [OR 1.86 (1.46–2.38)]. The literature search identified 618 studies initially; however, only three matched case-control studies (all in Caucasians) met the inclusion criteria for meta-analysis. Overall analysis showed that hypertension decreases PD risk by 0.2 times [OR 0.80 (0.66–0.96)]. Hypertension increases PD risk by 1.9 times in our Asian population. However, a meta-analysis comprising of Caucasian populations showed a protective effect of hypertension suggesting that ethnic differences or other genetic or environmental factors may contribute to the divergent observation. Early diagnosis and treatment of hypertension may potentially reduce the risk of PD, at least in our population.

Subject terms: Parkinson's disease, Parkinson's disease

Introduction

Parkinson’s disease (PD) is a debilitating neurodegenerative disorder clinically characterized by resting tremor, bradykinesia, rigidity, gait disturbances, and postural instability. In addition to motor impairments, PD is associated with many non-motor features, such as constipation, lower urinary tract symptoms, sleep disturbances, and neuropsychiatric symptoms1. PD incidence increases with age, with a rate of 32 per 100 000 among individuals 50 years or above in the Singapore population comprising predominantly of ethnic Han Chinese2. The disease burden is expected to increase in rapidly ageing populations.

The pathophysiology behind PD is complex and likely to be influenced by the interplay of genetic and environmental factors3. Environmental risk factors that might predispose individuals to PD remain to be fully elucidated. Hypertension is one of the most common chronic diseases globally. In our population, about 20% aged 18−69 years had hypertension4. Hypertension is known to increase the risk of cardiovascular diseases5 and is one of the leading risk factors for cerebral small vessel disease, as demonstrated in human and animal studies6,7. Hypertension accounts for high risk of mortality and substantial disability8. Dietary and lifestyle changes can potentially improve blood pressure control, preventing hypertension, and decrease the risk of associated medical complications5.

The etiologic link between hypertension and PD has been debated9, with studies showing divergent results10,11. The neurodegenerative effect is postulated to be caused by vasculopathy leading to strategic infarcts that could affect dopaminergic cells and disrupt neuronal connections12. The vasculopathy pattern differs between Asians and Caucasians with Asians being more likely to suffer from small vessel strokes13,14. To date, there is a paucity of data on the association between hypertension and PD.

To address the gaps in current knowledge, we investigate the association between hypertension and PD risk utilizing a matched case-control study. In addition, we performed a pooled analysis of similar matched case-control studies to further explore the association of hypertension on PD risk.

Results

Hypertension and risk of PD

A total of 1342 subjects comprising of 671 PD and 671 age and gender-matched controls were included.

The mean age of cases and controls were 63.9 ± 9.7 and 63.5 ± 9.8 years respectively. Gender distribution was equal for both cases and controls, with 59.5% males and 40.5% females in each group. PD cases were more likely to have hypertension (46.1%) (Table 1). The proportion of smokers and non-smokers was equal in cases and controls. The presence of hypertension was significantly associated with a higher odds of PD risk compared to the absence of hypertension [OR 1.86 (1.46–2.38)] after adjusting for age and gender (Table 2). When further adjusted for potential vascular confounders including diabetes, hyperlipidemia, and smoking status, our results remained significant, [OR 1.52 (1.17–1.98)].

Table 1.

Baseline characteristics of PD cases and controls.

Variable PD (n = 671) Controls (n = 671) P value
Demographics
Age (Years) 63.9 ± 9.72 63.5 ± 9.84 Matching factor
Male gender (%) 399 (59.5) 399 (59.5) Matching factor
Hypertension (%) 309 (46.1) 214 (31.9) <0.0001
Open in a new tab

Table 2.

Summary of matched case-control studies on the association of hypertension with risk of Parkinson’s disease.

Study Country Sample size Assessment of hypertension OR (95% CI) P value Matching criteria
Current study Singapore 671 PD, 671 controls Questionnaire and medical record 1.86 (1.46–2.38) <0.0001 Gender, age
Paganini-Hill17 USA 395 PD, 2320 controls Questionnaire 0.71 (0.56–0.89) None Gender, age, vital status
Powers et al.16 USA Males: 217 PD, 298 controls Questionnaire 0.80 (0.55–1.17) None Gender, age, area
Becker et al.15 UK 3637 PD, 3637 controls Medical record 0.83 (0.74–0.92) 0.001 Gender, age, general practice, index date, and duration of previous history
Open in a new tab

Meta-analysis of matched case-control studies

Our literature search identified an initial 618 studies in which 22 articles were duplicates and excluded. After the screening of the titles and abstracts, as well as assessment of eligibility criteria, only three studies with matched case-control samples, were included in the meta-analysis. The detailed selection process is shown in Fig. 1. The characteristics of included studies are shown in Table 2.

Fig. 1.

Fig. 1

Open in a new tab

Selection for included studies in meta-analysis.

A meta-analysis of matched case-control studies showed a protective effect of hypertension on the risk of PD. The association was significant after adjustment for potential confounders [OR 0.80 (0.66–0.96)] (Fig. 2). There was considerable heterogeneity among studies in the pooled analysis (I2 = 58%).

Fig. 2. Forest plot of pooled analysis for matched case-control studies on the association of hypertension with risk of Parkinson’s disease.

Fig. 2

Open in a new tab

Individual and overall ORs and the corresponding 95% CIs are reported. The size of the box is proportional to the weight assigned to each study, and the horizontal lines represent the 95% CIs.

Discussion

Utilizing a closely matched case-control methodology, our study suggested that hypertension is associated with an increased PD risk in our Asian population. In comparison, pooled analysis of matched case-control studies, which comprised of Caucasian populations showed that hypertension is associated with reduced risk of PD.

Epidemiologic studies on hypertension generally had inconsistent associations with PD9. These discrepancies could be explained by heterogeneity in the study population and design. Although subgroup analysis or meta-regression was not performed, we observed that all three included studies had a similar effect, indicating an inverse relationship of hypertension with PD15–17. This could suggest that the source of heterogeneity might be due to variations in magnitude instead of the direction of effects. The heterogeneity could also arise from different study designs. The studies included had mostly different numbers of PD cases and controls. One study was a nested case-control study, which explained the relatively high sample size of 3637 PD and 3637 controls, compared to the other two case-control studies with varying sample sizes as well. Moreover, the studies have adjusted for different confounders, which further substantiate that the heterogeneity could come from the adjustment for different covariates. There were no Asian studies included in this meta-analysis as these studies did not meet our inclusion criteria. Either no matching was performed, or the focus of analysis was not between PD cases and controls.

In our analysis, all three published studies had a higher proportion of hypertension in the controls. Whereas in our study, a higher proportion was observed in PD cases. This divergent observation could be explained by a variance in prevalence of PD and hypertension in different populations, ethnic-specific genetic factors, or exposure to environmental agents or lifestyle habits, or a combination of these factors. Both PD and hypertension are chronic diseases with rising prevalence globally. It has been shown that the prevalence of PD is lower in Asian countries such as China and Japan, compared to a higher prevalence in Western populations18. A low prevalence of hypertension was seen in Koreans and Chinese compared with Caucasians19,20. However, certain Asian races such as Filipinos had a higher prevalence of hypertension20.

Interestingly, some studies, which did not satisfy our meta-analysis inclusion criteria showed that hypertension was significantly associated with increased risk of PD among Asians11, corroborating our observation. If we have included studies with non-matched samples in our meta-analysis, there is a shift in trend towards higher odds of PD risk in the presence of hypertension (data not shown). Multiple non-matched Western studies have also established that hypertension increases PD risk12,21,22. In the Asian population, cohort studies in Taiwan showed an increased risk of PD in the presence of hypertension23,24, this is also seen in the Korean population25. However, a study in Japan showed that hypertension is associated with a decreased risk of PD26. These differences suggest potential underlying heterogeneity and subgroup variation, which could be attributed to many factors such as ethnic-specific genes or differences in lifestyle habits.

Emerging studies suggest that hypertension might share similar pathogenic pathways with PD, although exact mechanisms remain to be elucidated and require further investigations from in-vitro and animal models. The advantageous effect of hypertension on PD was postulated to be due to persistent elevation of cerebral blood flow16. Given that hypertension is one of the major risk factors of cerebral small vessel disease and has shown to contribute to cognitive decline and Alzheimer’s disease6, it is highly plausible that hypertension could result in greater PD risk. Chronic hypertension leading to infarcts at strategic locations such as the basal ganglia could disrupt dopaminergic cells and neuronal connections, subsequently leading to cerebrovascular dysfunction as suggested by pathological and imaging studies27,28. Furthermore, long-standing hypertension increases the risk of oxidative stress, resulting in reduced cerebral perfusion, which could decrease oxygen delivery to brain regions implicated in PD that are highly susceptible to ischemia29,30.

It has been suggested that reduced sympathetic activity in PD, due to decreased in levels or blunted activity of hormones involved in the sympathetic nervous system, could possibly explain the inverse relationship between hypertension and PD31. PD-induced harmful alterations to the autonomic nervous systems were shown. However, in addition to the sympathetic nervous system, the parasympathetic function is impaired as well. This results in the decreased ability to regulate blood pressure changes leading to a higher ambulatory blood pressure variability in PD32. A greater understanding of the pathogenesis pathways would be necessary to form the basis for the future development of pharmacological interventions in PD.

Our study involved a closely matched case-control data set. In addition, as Asian ethnicity may be varied (just like Caucasian race), we have only included ethnic Han Chinese, thus reducing racial difference as a confounding factor. It is unclear if our findings could be extrapolated to other populations since the underlying gene and environmental exposures may be ethnic-specific. Further studies in well-designed large prospective studies to better understand the interplay of environmental and gene factors, and the pathogenic mechanisms of PD are warranted. We have included matched studies with at least 200 cases and 200 controls in our meta-analysis because small unmatched studies are at a higher risk of both type 1 and type 2 errors. Future matched case-control studies in the Asian populations should be performed to corroborate our findings.

There is potential for our findings to contribute to the institution of behavioral modification interventions including lifestyle modifications or dietary recommendations for PD patients and asymptomatic high-risk populations to mitigate disease risk. Studies at the molecular level can be used to investigate the effects of hypertension on PD. These will be essential in elucidating the shared biomolecular mechanisms underlying both chronic diseases. A better understanding of the pathophysiology could form the basis for the future development of individualized disease-modifying therapies in PD33.

We demonstrated that hypertension increases PD risk by 1.9 times in our Asian population. However, our meta-analysis comprising studies in Caucasian populations was unable to replicate the finding suggesting that ethnic differences may contribute to divergent observation. Future longitudinal studies to evaluate the role of ethnic-specific gene variants in mediating the interaction between hypertension and PD will be of interest. Our study also suggests that early diagnosis and treatment of hypertension may potentially reduce the risk of PD, at least in our population.

Methods

Study subjects

Patients diagnosed with PD by movement disorder neurologists according to the UK PD Society Brain Bank clinical diagnostic criteria34 were recruited as cases at two major movement disorders centers. Healthy controls were volunteers without neurodegenerative diseases and examined by the investigators. We have only included ethnic Han Chinese in our study. For every PD patient, we looked for a similar age (± 2 years) and gender-matched control subjects.

The study received approval from the Singapore General Hospital/Singhealth institutional ethics committee (2002/08/A). Subjects have given written informed consent. The methods were carried out in accordance with the approved guidelines.

Assessment of hypertension

We used a previously validated questionnaire to obtain clinical information on hypertension, demographics, and family history of movement disorders from participants35. A response was coded as “No” if the subject never had hypertension and “Yes” if the subject was diagnosed with the condition by their physicians, supported by the use of prescribed medications. In addition to self-reported blood pressures, objective measurement was performed in clinics during recruitment. Subjects with high blood pressures during the clinical examination were subsequently diagnosed with hypertension and classified as hypertension for the purpose of this study.

Literature search and eligibility criteria

A database search using PubMed from the last 20 years (2000–2020) was performed. The following search terms were used: (“Parkinson’s disease” or “Parkinson disease”) and (“hypertension” or “high blood pressure”). Studies that met the following eligibility criteria were included for meta-analysis. Inclusion criteria included: (1) publications limited to English and human subjects only; (2) at least 200 cases and 200 controls comparing hypertension between PD cases and controls; (3) age and gender must be closely matched in cases and controls (age difference of at most ±3 years); (4) available data on the frequency of hypertension, age, and gender in cases and controls; (5) assessment of hypertension was provided; (6) PD diagnosis criteria were provided; (7) available data on odds ratio (OR), relative risk (RR) or hazard ratio (HR) and 95% confidence interval (CI).

Studies were excluded based on the following criteria: (1) studies without original data such as reviews or letters; (2) not matched for both age and gender; (3) wide age difference in matching (> ±3 years); (4) OR, RR or HR, and 95% CI were not provided or could not be derived from calculations based on available data.

Statistical methods

Subjects with demographic data for age, gender, and hypertension were included in the analysis. Baseline characteristics were reported using descriptive statistics and were compared between PD and controls using McNemar test. OR with 95% CI were derived from conditional logistic regression models adjusted for age and gender to study the independent effect of hypertension with PD risk. In the meta-analysis, a random-effects model was used to derive pooled OR with 95% CI given I2 > 50%. Subgroup analysis and meta-regression were not performed given the small number of available studies36. The significance level was set at p < 0.05. An I2 value that is more than 50% would indicate the presence of significant heterogeneity37,38.

Data analysis was performed using SPSS (IBM Corp. Released 2010. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp.). Meta-analysis was performed usingReview Manager (RevMan) [Computer program]. Version 5.4.1 The Cochrane Collaboration, 2020.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Supplementary information

Reporting Summary (2MB, pdf)

Acknowledgements

We thank the national medical research council (STaR and PD LCG 002) and staff who have assisted in collating the data for their support. The study is supported by the Singapore Ministry of Health’s National Medical Research Council (SPARKS grant).

Author contributions

E.N., E.W.L., K.M.P., L.T., and E.K.T. contributed to the recruitment of subjects. Y.F.N. and E.K.T. were involved in the analysis of the data. All authors contributed to the final paper.

Data availability

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at 10.1038/s41531-021-00202-w.

References

  • 1.Khoo TK, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80:276–281. doi: 10.1212/WNL.0b013e31827deb74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Tan LC, Venketasubramanian N, Jamora RD, Heng D. Incidence of Parkinson’s disease in Singapore. Parkinsonism Relat. Disord. 2007;13:40–43. doi: 10.1016/j.parkreldis.2006.07.003. [DOI] [PubMed] [Google Scholar]
  • 3.Delamarre A, Meissner WG. Epidemiology, environmental risk factors and genetics of Parkinson’s disease. Presse Med. 2017;46:175–181. doi: 10.1016/j.lpm.2017.01.001. [DOI] [PubMed] [Google Scholar]
  • 4.Epidemiology and disease control division. National Health Survey 2010 (Ministry of Health, Singapore, accessed 22 Sep 2020); https://www.moh.gov.sg/resources-statistics/reports/national-population-health-survey-2016-17
  • 5.Slama M, Susic D, Frohlich ED. Prevention of hypertension. Curr. Opin. Cardiol. 2002;17:531–536. doi: 10.1097/00001573-200209000-00014. [DOI] [PubMed] [Google Scholar]
  • 6.Liu Y, Dong YH, Lyu PY, Chen WH, Li R. Hypertension-induced cerebral small vessel disease leading to cognitive impairment. Chin. Med J. 2018;131:615–619. doi: 10.4103/0366-6999.226069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Yang Y, Kimura-Ohba S, Thompson J, Rosenberg GA. Rodent models of vascular cognitive impairment. Transl. Stroke Res. 2016;7:407–414. doi: 10.1007/s12975-016-0486-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ezzati M, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–1360. doi: 10.1016/S0140-6736(02)11403-6. [DOI] [PubMed] [Google Scholar]
  • 9.Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur. J. Epidemiol. 2011;26(Suppl 1):S1–S58. doi: 10.1007/s10654-011-9581-6. [DOI] [PubMed] [Google Scholar]
  • 10.Chen J, Zhang C, Wu Y, Zhang D. Association between hypertension and the risk of Parkinson’s disease: a meta-analysis of analytical studies. Neuroepidemiology. 2019;52:181–192. doi: 10.1159/000496977. [DOI] [PubMed] [Google Scholar]
  • 11.Hou L, et al. Hypertension and diagnosis of Parkinson’s disease: a meta-analysis of cohort studies. Front. Neurol. 2018;9:162. doi: 10.3389/fneur.2018.00162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kummer BR, et al. Associations between cerebrovascular risk factors and Parkinson disease. Ann. Neurol. 2019;86:572–581. doi: 10.1002/ana.25564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Tsai CF, Thomas B, Sudlow CL. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology. 2013;81:264–272. doi: 10.1212/WNL.0b013e31829bfde3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ueshima H, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation. 2008;118:2702–2709. doi: 10.1161/CIRCULATIONAHA.108.790048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology. 2008;70:1438–1444. doi: 10.1212/01.wnl.0000303818.38960.44. [DOI] [PubMed] [Google Scholar]
  • 16.Powers KM, et al. Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat. Disord. 2006;12:185–189. doi: 10.1016/j.parkreldis.2005.09.004. [DOI] [PubMed] [Google Scholar]
  • 17.Paganini-Hill A. Risk factors for parkinson’s disease: the leisure world cohort study. Neuroepidemiology. 2001;20:118–124. doi: 10.1159/000054770. [DOI] [PubMed] [Google Scholar]
  • 18.Zhang ZX, Roman GC. Worldwide occurrence of Parkinson’s disease: an updated review. Neuroepidemiology. 1993;12:195–208. doi: 10.1159/000110318. [DOI] [PubMed] [Google Scholar]
  • 19.Rodriguez F, Ferdinand KC. Hypertension in minority populations: new guidelines and emerging concepts. Adv. Chronic Kidney Dis. 2015;22:145–153. doi: 10.1053/j.ackd.2014.08.004. [DOI] [PubMed] [Google Scholar]
  • 20.Zhao B, et al. Racial/ethnic differences in hypertension prevalence, treatment, and control for outpatients in northern California 2010−2012. Am. J. Hypertens. 2015;28:631–639. doi: 10.1093/ajh/hpu189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Friedman B, Lahad A, Dresner Y, Vinker S. Long-term statin use and the risk of Parkinson’s disease. Am. J. Manag. Care. 2013;19:626–632. [PubMed] [Google Scholar]
  • 22.Pupillo E, et al. Epidemiology of Parkinson’s disease: a population-based study in primary care in Italy. Neuroepidemiology. 2016;47:38–45. doi: 10.1159/000448402. [DOI] [PubMed] [Google Scholar]
  • 23.Lai SW, Liao KF, Lin CL, Lin CC, Sung FC. Hearing loss may be a non-motor feature of Parkinson’s disease in older people in Taiwan. Eur. J. Neurol. 2014;21:752–757. doi: 10.1111/ene.12378. [DOI] [PubMed] [Google Scholar]
  • 24.Lai SW, Lin CL, Liao KF, Chang-Ou KC. Increased risk of Parkinson’s disease in cataract patients: a population-based cohort study. Parkinsonism Relat. Disord. 2015;21:68–71. doi: 10.1016/j.parkreldis.2014.11.005. [DOI] [PubMed] [Google Scholar]
  • 25.Nam GE, et al. Metabolic syndrome and risk of Parkinson disease: a nationwide cohort study. PLoS Med. 2018;15:e1002640. doi: 10.1371/journal.pmed.1002640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Miyake Y, et al. Case-control study of risk of Parkinson’s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J. Neurol. Sci. 2010;293:82–86. doi: 10.1016/j.jns.2010.03.002. [DOI] [PubMed] [Google Scholar]
  • 27.Greenberg SM, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8:165–174. doi: 10.1016/S1474-4422(09)70013-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson’s disease. A postmortem study. Acta Neuropathol. 2003;105:415–419. doi: 10.1007/s00401-003-0676-3. [DOI] [PubMed] [Google Scholar]
  • 29.Qiu C, et al. Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK study. Hypertension. 2011;57:1094–1100. doi: 10.1161/HYPERTENSIONAHA.111.171249. [DOI] [PubMed] [Google Scholar]
  • 30.Pires PW, Dams Ramos CM, Matin N, Dorrance AM. The effects of hypertension on the cerebral circulation. Am. J. Physiol. Heart Circ. Physiol. 2013;304:H1598–H1614. doi: 10.1152/ajpheart.00490.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Scigliano G, et al. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke. 2006;37:1184–1188. doi: 10.1161/01.STR.0000217384.03237.9c. [DOI] [PubMed] [Google Scholar]
  • 32.Kanegusuku H, et al. Patients with Parkinson disease present high ambulatory blood pressure variability. Clin. Physiol. Funct. Imaging. 2017;37:530–535. doi: 10.1111/cpf.12338. [DOI] [PubMed] [Google Scholar]
  • 33.Buhat DM, Tan EK. Genetic testing of LRRK2 in Parkinson’s disease: is there a clinical role? Parkinsonism Relat. Disord. 2014;20(Suppl 1):S54–S56. doi: 10.1016/S1353-8020(13)70015-4. [DOI] [PubMed] [Google Scholar]
  • 34.Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 1992;55:181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Yip CW, Tan EK. Test-retest repeatability of assessing environmental and lifestyle factors in Parkinson’s disease. Mov. Disord. 2008;23:1032–1036. doi: 10.1002/mds.21627. [DOI] [PubMed] [Google Scholar]
  • 36.Fu, R. et al. in Methods Guide for Effectiveness and Comparative Effectiveness Reviews (AHRQ Methods for Effective Health Care, 2008).
  • 37.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi: 10.1136/bmj.327.7414.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Song F, Sheldon TA, Sutton AJ, Abrams KR, Jones DR. Methods for exploring heterogeneity in meta-analysis. Eval. Health Prof. 2001;24:126–151. doi: 10.1177/016327870102400203. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Reporting Summary (2MB, pdf)

Data Availability Statement

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Articles from NPJ Parkinson's Disease are provided here courtesy of Nature Publishing Group

RESOURCES